{
    "clinical_study": {
        "@rank": "153003", 
        "arm_group": {
            "arm_group_label": "patient on hemodialysis taking plavix", 
            "description": "patient on hemodialysis taking plavix"
        }, 
        "brief_summary": {
            "textblock": "The investigators are trying to find out if Clopidogrel (Plavix) is as effective in\n      hemodialysis patients as in patients not hemodialysed."
        }, 
        "brief_title": "Prevalence of Clopidogrel (Plavix) Resistance in Hemodialysis Patients", 
        "completion_date": {
            "#text": "April 2011", 
            "@type": "Actual"
        }, 
        "condition": "Cardiovascular Disease", 
        "condition_browse": {
            "mesh_term": "Cardiovascular Diseases"
        }, 
        "detailed_description": {
            "textblock": "Cardiovascular disease is very frequent in hemodialysis patients. Lot of hemodialysis\n      patients are on Clopidogrel (plavix). Their is some evidence that clopidogrel is not\n      effective in hemodialysis as it is effective in patient without kidney problem.\n\n      VerifyNow plavix is a machine that measure the ability of the blood to clot after giving\n      plavix.\n\n      We will collect blood from hemodialysis patients on plavix and check the ability of their\n      blood to clot and thus indirectly measuring the efficacy of Plavix."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All patients on hemodialysis taking Plavix\n\n        Exclusion Criteria:\n\n          -  known to have bleeding disorder\n\n          -  Severely anemic with hemoglobin level (Hb) < 10g/dl\n\n          -  Low Platelets < 10000"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Hemodialysis patients who are taking plavix daily"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 9, 2010", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01865890", 
            "org_study_id": "10-016"
        }, 
        "intervention_browse": {
            "mesh_term": "Clopidogrel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Plavix or clopidogrel resistance", 
        "lastchanged_date": "May 30, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Staten Island", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10305"
                }, 
                "name": "Staten Island University Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prevalence of Clopidogrel (Plavix) Resistance in Hemodialysis Patients", 
        "overall_official": {
            "affiliation": "Staten Island University Hospital", 
            "last_name": "Suzanne El-Sayegh, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Plavix resistance is reported using the PRU values given by the VerifyNow machine.  PRU is P2Y12 Reaction Units which is correlated with platelet aggregation.", 
            "measure": "Prevalence Of Plavix resistance", 
            "safety_issue": "No", 
            "time_frame": "1 day ( one study visit)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01865890"
        }, 
        "responsible_party": {
            "investigator_affiliation": "North Shore Long Island Jewish Health System", 
            "investigator_full_name": "Suzanne El-Sayegh", 
            "investigator_title": "Nephrology Attending, Assoc. Chair of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Coronary Artery Disease (CAD) is very common in dialysis patients.  Treatment of CAD include medical therapy, stent placement and surgery.  Since Plavix is a medication that is commonly used after stent placement, we would like to assess the efficacy of this medication in this patient population.", 
            "measure": "assess the risk factors for plavix resistance in the hemodialysis population", 
            "safety_issue": "No", 
            "time_frame": "1 day (one  study visit)"
        }, 
        "source": "North Shore Long Island Jewish Health System", 
        "sponsors": {
            "collaborator": {
                "agency": "Staten Island University Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "North Shore Long Island Jewish Health System", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2013"
    }
}